目的 探討吉非替尼與重組人血管內(nèi)皮抑制素注射液聯(lián)合治療非小細胞肺癌的臨床療效及安全性。方法 以河南省直第三人民醫(yī)院2012年1月—2014年1月58例非小細胞肺癌化療患者為研究對象，根據(jù)入院單雙號將入選者隨機分為對照組和研究組，每組29例，對照組患者單用吉非替尼治療，研究組患者在此基礎(chǔ)上聯(lián)合重組人血管內(nèi)皮抑制素注射液治療，21 d為1個療程，共進行4個療程。比較兩組患者的臨床療效、各腫瘤標志物水平變化、不良反應(yīng)發(fā)生率及預后情況。結(jié)果 研究組及對照組患者客觀緩解率（ORR）分別為86.21%、55.17%，兩組比較存在顯著性差異（P<0.05）。治療前兩組患者各腫瘤標志物水平比較無顯著性差異，治療后兩組患者各腫瘤標志物水平均顯著降低，前后比較存在顯著性差異（P<0.05）；治療后研究組患者各腫瘤標志物水平降低程度顯著優(yōu)于對照組，兩組比較存在顯著性差異（P<0.05）。隨訪3年后，研究組患者的生存率、中位生存期及中位無進展生存期均顯著高于對照組，兩組比較存在顯著差異性（P<0.05），兩組不良反應(yīng)的發(fā)生率比較無顯著性差異。結(jié)論 吉非替尼與重組人血管內(nèi)皮抑制素注射液聯(lián)合應(yīng)用可有效提高臨床療效，延長生存期，降低各腫瘤標志物水平，且不增加不良反應(yīng)，安全性較高，值得在非小細胞肺癌的治療中進行推廣。

Objective To explore clinical efficacy and safety of Gefitinib combined with Endostar in treating non-small cell lung cancer (NSCLC). Methods 58 Patients with NSCLC were selected as the subjects from January 2013 to January 2015. According to the admission of single and double numbers were randomly divided into the control group and study group with 29 cases in each. The control group patients were treated with Gefitinib, the experimental group on the basis of this combination of Endostar. Compared the two groups of patients with clinical effect, tumor marker levels changes, incidence of adverse reactions and prognosis. Results The patients' ORR in the study group were 86.21%, which was significantly higher than in the control group (P<0.05). Before treatment, there was no significant difference in the level of tumor markers between the two groups, after treatment, the level of tumor markers was significantly decreased in both groups and there were significant differences between before and after (P<0.05). The level of tumor markers in the study group was significantly better than that in the control group (P<0.05). After 3 years of follow-up, the survival rate, median survival and median progression-free survival of the study group were significantly higher than those of the control group and there was significant difference (P<0.05), The incidence of adverse reactions had no statistically significant differences between the two groups. Conclusions Gefitinib combined with Endostar in treating NSCLC can effectively improve clinical effect, extend the survival period, reduce the level of tumor markers, don't increase the adverse reactions and higher safety, which has worthy of promotion.